Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials

Petty GW, Brown RD, Whisnant JP, Sicks JRD, O’Fallon WM, Wiebers DO: Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999, 30 (12): 2513-2516. 10.1161/01.STR.30.12.2513.

Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001, 32 (12): 2735-2740. 10.1161/hs1201.100209.

Schulz UG, Rothwell PM: Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke. 2003, 34 (8): 2050-2059. 10.1161/01.STR.0000079818.08343.8C.

Schneider AT, Kissela B, Woo D, Kleindorfer D, Alwell K, Miller R, Szaflarski J, Gebel J, Khoury J, Shukla R: Ischemic stroke subtypes A population-based study of incidence rates among blacks and whites. Stroke. 2004, 35 (7): 1552-1556. 10.1161/01.STR.0000129335.28301.f5.

Lee BI, Nam HS, Heo JH, Kim DI: Yonsei stroke registry. Cerebrovasc Dis. 2001, 12 (3): 145-151. 10.1159/000047697.

De Castro S, Cartoni D, Fiorelli M, Rasura M, Anzini A, Zanette EM, Beccia M, Colonnese C, Fedele F, Fieschi C: Morphological and functional characteristics of patent foramen ovale and their embolic implications. Stroke. 2000, 31 (10): 2407-2413. 10.1161/01.STR.31.10.2407.

Mas JL, Zuber M: Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J. 1995, 130 (5): 1083-1088. 10.1016/0002-8703(95)90212-0.

Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G, On behalf of Lausanne Stroke with Paradoxal Embolism Study Group: Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology. 1996, 46: 1301-1305. 10.1212/WNL.46.5.1301.

Cabanes L, Mas J, Cohen A, Amarenco P, Cabanes P, Oubary P, Chedru F, Guerin F, Bousser M, De Recondo J: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993, 24 (12): 1865-1873. 10.1161/01.STR.24.12.1865.

Comess KA, DeRook FA, Beach KW, Lytle NJ, Golby AJ, Albers GW: Transesophageal echocardiography and carotid ultrasound in patients with cerebral ischemia: prevalence of findings and recurrent stroke risk. J Am Coll Cardiol. 1994, 23 (7): 1598-1603. 10.1016/0735-1097(94)90662-9.

Di Tullio M, Sacco RL, Gopal A, Mohr J, Homma S: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Int Med. 1992, 117 (6): 461-10.7326/0003-4819-117-6-461.

Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr J: Effect of medical treatment in stroke patients with patent foramen ovale. Circulation. 2002, 105 (22): 2625-2631. 10.1161/01.CIR.0000017498.88393.44.

Lechat P, Lascault G, Mas J, Loron P, Klimczac K, Guggiari M, Drobinski G, Fraysse J, Thomas D, Grosgogeat Y: Prevalence of patent foramen ovale in young patients with ischemic cerebral complications]. Arch des Maladies du coeur et des vaisseaux. 1989, 82 (6): 847-

Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med. 2001, 345 (24): 1740-1746. 10.1056/NEJMoa011503.

Webster M, Smith H, Sharpe D, Chancellor A, Swift D, Bass N, Glasgow G: Patent foramen ovale in young stroke patients. Lancet. 1988, 332 (8601): 11-12. 10.1016/S0140-6736(88)92944-3.

Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O'Fallon WM, Pascoe RD, Enriquez-Sarano M, Seward JB, Covalt JL, Sicks JRD, Wiebers DO: Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc. 1999, 74 (9): 862-869. 10.4065/74.9.862.

Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clinic Proc. 1984, 59 (1): 17-20. 10.1016/S0025-6196(12)60336-X.

Khairy P, O'Donnell CP, Landzberg MJ: Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med. 2003, 139 (9): 753-760. 10.7326/0003-4819-139-9-200311040-00010.

Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T: Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke. 1997, 28 (9): 1702-1709. 10.1161/01.STR.28.9.1702.

Lamy C, Giannesini C, Zuber M, Arquizan C, Meder J, Trystram D, Coste J, Mas J: Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale the PFO-ASA study. Stroke. 2002, 33 (3): 706-711. 10.1161/hs0302.104543.

Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, Flaherty ML, Khatri P, Ferioli S, La Rosa FDLR: Age at stroke temporal trends in stroke incidence in a large, biracial population. Neurology. 2012, 79 (17): 1781-1787. 10.1212/WNL.0b013e318270401d.

Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, et al: Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012, 366 (11): 991-999. 10.1056/NEJMoa1009639.

Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL: Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013, 368 (12): 1092-1100. 10.1056/NEJMoa1301440.

Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, et al: Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013, 368 (12): 1083-1091. 10.1056/NEJMoa1211716.

Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR: Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. JACC Cardiovas Intervent. 2012, 5 (7): 777-789. 10.1016/j.jcin.2012.02.021.

Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM: Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke J Cereb Circulation. 2012, 43 (2): 422-431. 10.1161/STROKEAHA.111.631648.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med. 2009, 151 (4): W264-269. 10.7326/0003-4819-151-4-200908180-00135.

Ford MA, Reeder GS, Lennon RJ, Brown RD, Petty GW, Cabalka AK, Cetta F, Hagler DJ: Percutaneous device closure of patent foramen ovale in patients with presumed cryptogenic stroke or transient ischemic attack: the Mayo Clinic experience. JACC Cardiovasc Intervent. 2009, 2 (5): 404-411. 10.1016/j.jcin.2008.12.015.

Heinisch C, Bertog S, Wunderlich N, Majunke N, Baranowski A, Leetz M, Fischer E, Staubach S, Zimmermann W, Hofmann I, et al: Percutaneous closure of the patent foramen ovale using the HELEX(R) Septal Occluder: acute and long-term results in 405 patients. EuroIntervent J EuroPCR Collabor Working Group Intervent Cardiol Euro Soc Cardiol. 2012, 8 (6): 717-723.

Li Y, Zhou K, Hua Y, Wang C, Xie L, Fang J, Rong X, Shen J: Amplatzer occluder versus CardioSEAL/STARFlex occluder: a meta-analysis of the efficacy and safety of transcatheter occlusion for patent foramen ovale and atrial septal defect. Cardiol Young. 2013, 23 (4): 582-596. 10.1017/S1047951112001424.

Sievert H, Wunderlich N, Reiffenstein I, Ruygrok P, Grube E, Buellesfeld L, Meier B, Schofer J, Muller D, Jones RK, et al: Initial clinical experience with the Coherex Flatstent and Flatstent EF PFO closure system for in-tunnel PFO closure: results of the Coherex- EU study. Catheter Cardiovasc Interv. 2012, doi:10.1002/ccd.24565. [Epub ahead of print],

Stanczak LJ, Bertog SC, Wunderlich N, Franke J, Sievert H: PFO closure with the Premere PFO closure device: acute results and follow-up of 263 patients. EuroIntervention: J EuroPCR Collabor Working Group Intervent Cardiol Euro Soc Cardiol. 2012, 8 (3): 345-351. 10.4244/EIJV8I3A53.

Wahl A, Juni P, Mono ML, Kalesan B, Praz F, Geister L, Raber L, Nedeltchev K, Mattle HP, Windecker S, et al: Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012, 125 (6): 803-812. 10.1161/CIRCULATIONAHA.111.030494.